Glenmark Pharmaceuticals has scheduled a meeting of its board of directors on Friday, May 29, 2026. The meeting has been convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the standalone and consolidated audited financial results of the company for the quarter and year ended March 31, 2026. Additionally, the board will deliberate on and recommend a dividend on equity shares for the fiscal year ended March 31, 2026, if any.

Trading Window Closure

In accordance with the "Code of Conduct for Prevention of Insider Trading" and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has informed its directors and other designated persons about the closure of the trading window. This closure is effective from March 31, 2026, to May 31, 2026, inclusive, to facilitate the approval of the audited financial results.

The meeting will be held to review the company's financial performance for the full fiscal year and the final quarter. Shareholders and investors await the board's decision regarding the potential dividend declaration for the year ended March 31, 2026.

Glenmark Pharmaceuticals Inc., USA announced on May 18, 2026, the launch of Vancomycin Hydrochloride for Injection USP in two strengths — 500 mg/vial and 1 g/vial — from its base in Elmwood Park, New Jersey. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, of Fresenius Kabi USA, LLC. This launch further expands the company's injectable portfolio in the United States market.

Product and Market Overview

The newly launched product enters a market that has demonstrated notable commercial scale. According to IQVIA® National Sales Perspectives: Retail & Non-Retail data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of approximately $37.9 million. The market figure includes the brand and all available therapeutic equivalents.

Key details of the product launch are summarised below:

Leadership Commentary

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark's continued commitment to expanding access to quality, affordable medicines in the U.S. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients."

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with a focus on innovation and accessibility. The company operates 11 manufacturing facilities across four continents, supported by six R&D centres, and maintains a commercial presence in 80+ countries. Its diversified portfolio spans branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Note: Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is approved only for the indication(s) listed in Glenmark's approved label. IQVIA® data obtained by Glenmark is only available for all approved RLD indications; Glenmark's product is only approved for the indications listed in its approved label and is not marketed for all RLD indications.